Cargando…

Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery

Patient-centered therapeutic management for chronic medical conditions is a desired but unmet need, largely attributable to the lack of adequate technologies for tailored drug administration. While triggered devices that control the delivery of therapeutics exist, they often rely on impractical cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Trani, Nicola, Silvestri, Antonia, Sizovs, Antons, Wang, Yu, Erm, Donald R., Demarchi, Danilo, Liu, Xuewu, Grattoni, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249613/
https://www.ncbi.nlm.nih.gov/pubmed/32249279
http://dx.doi.org/10.1039/d0lc00121j
_version_ 1783538621467328512
author Di Trani, Nicola
Silvestri, Antonia
Sizovs, Antons
Wang, Yu
Erm, Donald R.
Demarchi, Danilo
Liu, Xuewu
Grattoni, Alessandro
author_facet Di Trani, Nicola
Silvestri, Antonia
Sizovs, Antons
Wang, Yu
Erm, Donald R.
Demarchi, Danilo
Liu, Xuewu
Grattoni, Alessandro
author_sort Di Trani, Nicola
collection PubMed
description Patient-centered therapeutic management for chronic medical conditions is a desired but unmet need, largely attributable to the lack of adequate technologies for tailored drug administration. While triggered devices that control the delivery of therapeutics exist, they often rely on impractical continuous external activation. As such, next generation continuously tunable drug delivery systems independent of sustained external activation remain an elusive goal. Here we present the development and demonstration of a silicon carbide (SiC)-coated nanofluidic membrane that achieves reproducible and tunable control of drug release via electrostatic gating. By applying a low-intensity voltage to a buried electrode, we showed repeatable and reproducible in vitro release modulation of three model analytes. A small fluorophore (Alexa Fluor 647), a large polymer poly(sodium 4-styrenesulfonate) and a medically relevant agent (DNA), were selected as representatives of small molecule therapeutics, polymeric drug carriers, and biological therapeutics, respectively. Unlike other drug delivery systems, our technology performed consistently over numerous cycles of voltage modulation, for over 11 days. Importantly, low power consumption and minimal leakage currents were achieved during the study. Further, the SiC coating maintained integrity and chemical inertness, shielding the membrane from degradation under simulated physiological and accelerated conditions for over 4 months. Through leveraging the flexibility offered by electrostatic gating control, our technology provides a valuable strategy for tunable delivery, setting the foundation for the next generation of drug delivery systems.
format Online
Article
Text
id pubmed-7249613
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-72496132020-05-26 Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery Di Trani, Nicola Silvestri, Antonia Sizovs, Antons Wang, Yu Erm, Donald R. Demarchi, Danilo Liu, Xuewu Grattoni, Alessandro Lab Chip Article Patient-centered therapeutic management for chronic medical conditions is a desired but unmet need, largely attributable to the lack of adequate technologies for tailored drug administration. While triggered devices that control the delivery of therapeutics exist, they often rely on impractical continuous external activation. As such, next generation continuously tunable drug delivery systems independent of sustained external activation remain an elusive goal. Here we present the development and demonstration of a silicon carbide (SiC)-coated nanofluidic membrane that achieves reproducible and tunable control of drug release via electrostatic gating. By applying a low-intensity voltage to a buried electrode, we showed repeatable and reproducible in vitro release modulation of three model analytes. A small fluorophore (Alexa Fluor 647), a large polymer poly(sodium 4-styrenesulfonate) and a medically relevant agent (DNA), were selected as representatives of small molecule therapeutics, polymeric drug carriers, and biological therapeutics, respectively. Unlike other drug delivery systems, our technology performed consistently over numerous cycles of voltage modulation, for over 11 days. Importantly, low power consumption and minimal leakage currents were achieved during the study. Further, the SiC coating maintained integrity and chemical inertness, shielding the membrane from degradation under simulated physiological and accelerated conditions for over 4 months. Through leveraging the flexibility offered by electrostatic gating control, our technology provides a valuable strategy for tunable delivery, setting the foundation for the next generation of drug delivery systems. 2020-05-05 /pmc/articles/PMC7249613/ /pubmed/32249279 http://dx.doi.org/10.1039/d0lc00121j Text en http://creativecommons.org/licenses/by-nc/3.0/ This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.
spellingShingle Article
Di Trani, Nicola
Silvestri, Antonia
Sizovs, Antons
Wang, Yu
Erm, Donald R.
Demarchi, Danilo
Liu, Xuewu
Grattoni, Alessandro
Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery
title Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery
title_full Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery
title_fullStr Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery
title_full_unstemmed Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery
title_short Electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery
title_sort electrostatically gated nanofluidic membrane for ultra-low power controlled drug delivery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249613/
https://www.ncbi.nlm.nih.gov/pubmed/32249279
http://dx.doi.org/10.1039/d0lc00121j
work_keys_str_mv AT ditraninicola electrostaticallygatednanofluidicmembraneforultralowpowercontrolleddrugdelivery
AT silvestriantonia electrostaticallygatednanofluidicmembraneforultralowpowercontrolleddrugdelivery
AT sizovsantons electrostaticallygatednanofluidicmembraneforultralowpowercontrolleddrugdelivery
AT wangyu electrostaticallygatednanofluidicmembraneforultralowpowercontrolleddrugdelivery
AT ermdonaldr electrostaticallygatednanofluidicmembraneforultralowpowercontrolleddrugdelivery
AT demarchidanilo electrostaticallygatednanofluidicmembraneforultralowpowercontrolleddrugdelivery
AT liuxuewu electrostaticallygatednanofluidicmembraneforultralowpowercontrolleddrugdelivery
AT grattonialessandro electrostaticallygatednanofluidicmembraneforultralowpowercontrolleddrugdelivery